Table 1. Clinical characteristics of patients (stratified according to IgA anti-β2GPI titer) and controls.
| Patients with isolated IgA anti-β2GPI | Controls | ||||
| Mild elevation (20–49 U/mL) | Moderate elevation (50–99 U/mL) | Severe elevation (≥100 U/ml) | Total | Total | |
| Number of patients (%) | 32 (57%) | 15 (27%) | 9 (16%) | 56 (100%) | 56 |
| Age (range) | 43.3 years (22–78) | 40.8 years (24–68) | 44.4 years (30–61) | 42.8 years (22–78) | 42.8 years (22–78) |
| Race | |||||
| African-American | 22 | 12 | 5 | 39 | 39 |
| Asian | 1 | 0 | 0 | 1 | 1 |
| Caucasian | 4 | 1 | 2 | 7 | 7 |
| Hispanic | 1 | 0 | 0 | 1 | 1 |
| Unknown | 4 | 2 | 2 | 8 | 8 |
| Gender | |||||
| Female | 30 | 13 | 7 | 50 | 50 |
| Male | 2 | 2 | 2 | 6 | 6 |
| Thromboembolic events † | |||||
| Number of patients (%) | 13 (41%) | 10 (67%) | 4 (44%) | 27 (48%) | 14 (25%) |
| Total Events | 17 | 14 | 7 | 38 | 18 |
| Arterial Events | 10 | 8 | 5 | 23 | 12 |
| Venous Events | 5 | 3 | 2 | 10 | 6 |
| TMA* | 2 | 3 | 0 | 5 | 0 |
| SLE * status | |||||
| SLE | 16 | 11 | 4 | 31 | 32 |
| Non-SLE# | 16 | 4 | 5 | 25 | 24 |
*Abbreviations used in this table: SLE, systemic lupus erythematosus; TMA, thrombotic microangiopathy.
Among IgA anti-β2GPI positive patients, 5 had both an arterial and a venous event (3 with mild elevation, 1 with moderate elevation, 1 with severe elevation), 4 patients had both an arterial event and TMA (2 with mild elevation, 2 with moderate elevation), 1 patient had both a venous event and TMA (with moderate elevation), and 1 patient had 2 arterial events (with severe elevation). Among controls, 4 had both an arterial and a venous event.
Among IgA anti-β2GPI positive patients, non-SLE patients included the following autoimmune or rheumatologic diagnoses: Cogan's syndrome (n = 1), fibromyalgia (n = 1), Hashimoto's thyroiditis (n = 1), mixed connective tissue disease (n = 1), myelitis (n = 1), polycystic ovary syndrome (n = 1), sarcoidois (n = 1), scleroderma (n = 1), sickle cell anemia (n = 2), Sjögren's syndrome (n = 1), Tietze's syndrome (n = 1), and Wegener's granulomatosis (n = 1). Among controls, non-SLE individuals included: amyotrophic lateral sclerosis (n = 1), Behcet's syndrome (n = 1), chondrocalcinosis (n = 1), HELLP syndrome (n = 1), inflammatory polyarthropathy (n = 1), osteoporosis (n = 1), Raynaud's disease (n = 1), Sjögren's syndrome (n = 2), and ulcerative colitis (n = 1).